C
OMBINATION CHEMOTHERAPY became the mainstay of treatment for patients with extensive-stage small-cell lung cancer (SCLC) in the 1970s. 1 Combination chemotherapy regimens achieve initial response rates of 50% to 60% and median survival times of 7 to 11 months in patients with extensive-stage disease. 2, 3 Despite this, less than 3% of patients with extensive-stage SCLC achieve a 3-year survival time with currently available regimens. 4 A review of patients with extensive-stage SCLC treated at the National Cancer Institute, Bethesda, MD, over the last 20 years has recently been reported. 5 Despite diverse strategies for the treatment of these patients, the median survival time ranged from 6.3 to 11.3 months in different trials, and there has been no significant trend toward longer survival times for patients with extensive-stage SCLC who were treated more recently. These results are in contrast to the recent analysis by Aisner, 6 who reported in a selected review that patients with extensive-stage SCLC who were treated with higher doses of combination chemotherapy over the past 10 years have prolonged survival times compared with selected historical controls.
In light of these analyses of patients with extensive-stage SCLC, 5, 6 we chose to review all of the cooperative group North American phase III randomized therapeutic trials for patients with extensive-stage SCLC that have been performed during the same time period. The focus on this study is on patients with extensive-stage SCLC because this isolates the effects (benefits) of chemotherapy. Patients with limited-stage SCLC were not included because their treatment can include chest radiotherapy or surgery, which makes analyses more complicated. We evaluated the cooperative group trials because the trial information was readily retrievable from the Cancer Therapy Evaluation Program database, and information from pharmaceutical industrysponsored trials was not available from a central source. We examined whether the number of trials being initiated had changed, whether the number of patients enrolled onto the trials had increased or decreased over time, and whether changes had occurred in the survival time of patients treated on these trials. We also examined whether patients treated with newer experimental regimens lived significantly longer compared with patients treated with standard chemotherapy regimens.
The median and 5-year survival time information on patients with extensive-stage SCLC from the past 25 years is available on the Surveillance, Epidemiology, and End Results (SEER) database. 7 This database provided the data to compare the outcome of patients with extensive-stage SCLC in both cooperative groups and a population database. We also evaluated potential changes in patient survival time with the passage of time reported in our single-institution experience, 5 cooperative group studies, and the population database during the same time period.
PATIENTS AND METHODS

Phase III Trials
The phase III trials initiated for patients with extensive-stage SCLC were identified through a search of the National Cancer Institute Cancer Therapy Evaluation Program database for the time period between 1972 and 1990. We evaluated the trials initiated between 1972 and 1990 because this corresponded closely with the interval examined in our previous report 5 and because this time period allowed adequate time for patient enrollment onto a study, follow-up, and publication of the mature results of the therapeutic trials. The lung cancer committee chairs from each cooperative group in North America were contacted to inform them of this analysis and to determine whether additional trials had been performed that were not known to us. Information about each trial was obtained regarding the years of the trial, the number of patients enrolled onto the study, sex of the patients, treatment regimens used, response rates, median survival times, and the number patients deaths at the time of the analysis. The median of the median survival times was computed without adjusting for the sample size of the control arm, and the median survival time of patients before and after 1981 was not adjusted for trial size. Each study median was treated as a data point. Some phase III trials incorporated patients with both limited-and extensive-stage disease. Only patients with extensive-stage SCLC were included in this analysis. We acknowledge that the definitions of limited-and extensive-stage SCLC vary somewhat in the different cooperative groups. However, we did not attempt to reallocate patients based on these differences because of the difficulty of identifying which patients would be reallocated and then obtaining information on their characteristics and survival time. The control arms in each of the phase III trials were identified based on the statement of the authors in the published reports and were verified by contacting the group chair. A small minority of the phase III trials did not have all of this information available in the published article. In these cases, the author of the study and cooperative group statistician were contacted and additional data were obtained if available and the author permitted its use.
The SEER database was also examined to compare the median and 5-year survival time information for all patients with SCLC and those with extensive-stage SCLC versus our analysis of patients treated on phase III trials over the same time period. The time period from 1973 to 1994 was examined because the starting year corresponded most closely with the start of the cooperative group studies and 1994 corresponded most closely with the year the cooperative group trials finished their accrual. 7 In the SEER database, patients with metastatic disease are categorized as ''distant,'' which is roughly equivalent to extensive-stage disease. In this analysis, patients from the SEER database with distant disease are termed extensive-stage to be consistent with the terminology used in the cooperative group studies.
Statistical Methods
Least squares regression (linear and quadratic) was used to evaluate whether there were time trends in the numbers of patients enrolled or in survival time. 8 Because the enrollment dates for individual patients were not available, we distributed the patients evenly over the enrollment period. The dependent variable in the former analysis was the total annual accrual, and the independent variable was the calendar year. This analysis was also adjusted for the length of time that patients were enrolled onto each study. The patient information was also studied with multiple regression analyses using the ordinary least squares regression method, including year of treatment, proportion of female patients, and cisplatin-based chemotherapy, to determine whether these factors independently impacted on the survival time of patients with extensive-stage SCLC treated on phase III cooperative group studies over time. 8 The significance of each explanatory variable was tested by a t test. The trend in median survival time and 5-year survival among patients with SCLC recorded in the SEER database was calculated using a least squares regression analysis. All P values corresponded to two-sided tests. The two-sample t test and Wilcoxon test were used to compare the statistics between two time periods, 1972 to 1981 versus 1982 to 1990. The outcomes that were compared using the Wilcoxon test were the total number of patients in each study and the total number of patients on the control arms in each study.
RESULTS
Phase III Trials
Twenty-two North American cooperative group phase III trials that were initiated between 1972 and 1990 were identified. One study, performed between 1980 and 1984 by the Northern California Oncology Group, has yet to be published in either abstract or manuscript form. The data from this study cannot be referenced, so we did not include it in this analysis. The exclusion of this data did not appreciably alter the outcome of the study. We analyzed the treatment arms from the 21 published phase III trials. The results of these 21 cooperative group trials are listed in Table 1 
Survival Time of Patients
The median of the median survival times of patients treated on the control arms of the phase III trials over the entire period of analysis was 7.6 months. The median of the median survival times of patients treated on the control arms of the phase III trials initiated from 1972 to 1981 was 7.0 months and was 8.9 months for patients treated on trials initiated from 1982 to 1990 (Wilcoxon test, P ϭ .001). There has also been a significant trend toward prolonged survival time in patients treated on the control arms initiated over the entire period of this analysis (1972 to 1993, P ϭ .0001; Fig  1) . The increase in survival time may have been caused by changes in patient characteristics or an improvement in supportive care of these patients independent of the treatment received. The percentage of women entered onto the clinical trials was similar in the two decades: 28.8% in the trials initiated from1972 to 1981 and 29.9% in trials initiated from 1982 to 1990 (Wilcoxon test, P ϭ .57; trend, P ϭ .37). The increase in patient survival time over time also may have been caused by the transition to etoposide/cisplatin chemotherapy, which has been the standard treatment since the early 1980s. 1 In this analysis, the median survival time of patients treated with cisplatin-based regimens (n ϭ 14) was 9.5 months compared with 7.1 months for patients treated with non-cisplatin-based regimens (n ϭ 40). A least squares regression analysis that included the year of study initiation, sex (percentage of female patients), treatment group, and cisplatin-based chemotherapy showed that sex was not related to median survival time (P ϭ .10) but cisplatin-based therapy and the year of study initiation were significantly related to median survival time (P ϭ .04 and P ϭ .002, respectively).
Five (24%) of the 21 phase III trials showed a statistically significant difference in survival time in the group of patients who received experimental therapy compared with the control group ( The five studies that showed a significant difference in survival time 13 ,18,21,22,27 did not have a significantly larger number of patients enrolled (median, 84 patients per arm; range, 50 to 294) than the studies that did not show a difference in survival time (median, 88.5 patients per arm; range, 12 to 342; P ϭ .83). The study by Ettinger et al had the greatest number of patients enrolled (n ϭ 577) compared with all other studies. Despite only 0.8 months difference in median survival time of patients treated on the control arm compared with patients treated on the experimental arm, this trial showed a statistically significant difference in survival time. 
SEER Database
Information on the median and 5-year survival times of patients with extensive-stage SCLC is also available in the SEER population database. The observations about the changes in survival time of patients treated for SCLC in the SEER database were similar to the results observed for the cooperative groups. In the SEER database, the median survival time of patients with extensive-stage SCLC increased from a median of 6.5 months between 1973 and 1974 compared with 8.2 months for those treated between 1993 and 1994 (P ϭ .0001; Fig 2A) . The SEER data also suggest that there has been a modest but perceptible increase in the 5-year survival rates of patients with extensive-stage SCLC. Patients treated between 1973 and 1974 had a 5-year survival rate of 0.8% compared with a 5-year survival rate of 1.6% for those treated between 1989 and 1990 (P ϭ .0001).
The 5-year survival data are not available in the extensivestage trials reported in this article. This improvement in median survival time with the passage of time is similar to the results of our analysis of patients treated in cooperative group trials during the same time period. In the SEER database, the median survival time of patients with both limited-and extensive-stage SCLC has also modestly improved over the period of this analysis (Fig 2B) . The overall median survival time of all patients with SCLC treated between 1973 and 1974 was 7.3 months, compared with 9.3 months for patients treated between 1993 and 1994 (P ϭ .0001). The 5-year survival rate of all patients with SCLC treated between 1973 and 1974 was 3.4%, compared with 7.1% for those treated between 1991 and 1992 (P ϭ .0001).
DISCUSSION
Analysis of North American cooperative group phase III trials for patients with extensive-stage SCLC initiated between 1972 and 1990 demonstrated that there was no significant change in the number of trials instituted or the number of patients enrolled onto phase III trials over time. In addition, our review of the North American cooperative group trials for patients with extensive-stage SCLC revealed that only six phase III trials were initiated in North America between 1984 and 1990 and none between 1990 and 1993. These results may be consistent with a declining interest on the part of physicians in the enrollment of patients with extensive-stage SCLC onto phase III trials. It also may reflect a paucity of ideas regarding innovative treatments for patients with extensive-stage SCLC. The advent of etoposide and cisplatin as standard therapy in the early 1980s may also have caused a decline in the number of trials being initiated and the number of patients being referred for phase III trials. Since the combination of etoposide and cisplatin was introduced in the treatment of this disease, there has been a significant lack of new drugs to use until recently. In this study, a least squares regression analysis demonstrated that cisplatin-based chemotherapy and the year of treatment were significantly associated with improved median survival time over the years (P ϭ .04 and P ϭ .002, respectively). The improvement in survival time was independently associated with both cisplatin-based therapy as well as the passage of time. Therefore, the increase in survival time observed with the passage of time was contributed to by factors other than the transition to etoposide and cisplatin therapy. We speculate that the other factor that most likely has contributed to the prolongation of patient survival over time is the improvement in the supportive care and general medical management of these patients. The association between cisplatin-based treatment and prolonged survival has also been observed in a recent meta-analysis of trials for patients with metastatic non-SCLC. 30 Sixteen (76%) of the 21 phase III cooperative group therapeutic trials for patients with extensive-stage SCLC showed no difference in the survival time of patients between the experimental and standard arms regardless of the treatment regimens used. Three of the five studies 13, 18, 27 that showed a significant difference between the experimental and control arms had median survival times in the control arms that were lower than the median survival time of patients in the SEER database treated during the same time period (7.0, 7.1, and 7.3 months in the phase III trials v 7.2, 7.3, and 7.9 months in the SEER database). The relatively poor outcome of patients in the control arm of these three phase III studies may have contributed to the significant differences in survival times that were observed in these trials.
Despite diverse treatment strategies, the longest median survival time achieved in any of the experimental arms of the cooperative group studies was 12.3 months, and only four (19%) of the 21 phase III trials that we reviewed demonstrated a median survival time in the experimental arm of greater than 11 months. These results demonstrate that experimental regimens that investigators believe are promising in pilot or phase II studies rarely show prolonged survival when these regimens are compared with standard treatments for patients with extensive-stage SCLC.
Although we observed a significant trend (P ϭ .0001) toward a 2-month prolongation in patient median survival time over the 22 years of this analysis, there was no significant improvement in median survival time over the past 10 years (P ϭ .27). The early phase III studies (between 1972 and 1981) had relatively short median survival times on the control arms, which included two studies that used single-agent cyclophosphamide as control treatment. 9, 11 The lack of change in patient survival time over the past 10 years contrasts with the conclusions presented recently by another investigator who reviewed selected aggressive chemotherapy regimens for patients with extensive-stage SCLC over the past 30 years and concluded that survival time of these patients was improving over the years. 6 The lack of change in patient survival time that we observed over the past 10 years may reflect the consistent use of CAV or etoposide and cisplatin in the control arms of trials for patients with extensive-stage SCLC during that time period. These regimens have been shown in randomized studies to achieve similar survival times for patients with extensive-stage SCLC. 24, 31 In light of our observations that 22 years of clinical research has achieved only a 2-month improvement in the survival time of patients with extensive-stage SCLC, one must consider the economic impact and quality-of-life issues that surround the treatment of this disease. Studies of the quality of life of patients with extensive-stage SCLC have produced conflicting results. A study by Earl et al 32 demonstrated that patients who received standard chemotherapy on schedule had a significantly improved quality of life compared with patients who received chemotherapy only as symptoms dictated. Another study found that weekly doseintensive chemotherapy was associated with a significant decline in patient quality of life, whereas patients receiving the same chemotherapy given every 3 weeks had significantly less change in their quality-of-life parameters. 33 Similar studies of quality of life in patients with non-SCLC receiving chemotherapy indicate that most patients report improvements in quality-of-life parameters once treatment is initiated. 34 Although we were unable to retrieve information on patient quality of life in this study, the limited changes we observed in patient survival time suggest that a greater effort to apply new, experimental agents is indicated for patients with this disease.
A comparison of the median survival time of patients with extensive-stage SCLC in the SEER database showed significantly prolonged median survival times of slightly less than 2 months in the group treated between 1993 and 1994 compared with the group treated between 1973 and 1974. The trend toward prolongation in survival has continued from 1977 to 1989 (Fig 2A) . The SEER data corresponded with the modest trend for a prolongation of survival for patients with extensive-stage SCLC treated in cooperative group therapeutic trials over the past 20 years. This prolongation in the survival of patients with extensive-stage SCLC could have been caused by stage migration because of improved technology for imaging metastatic sites developed during the last 20 years, a phenomena referred to as the Will Rogers effect. 35 If this were the case, we would expect there to be a prolongation in survival for each stage without an overall improvement. However, the SEER data suggest that there has been a prolongation in the survival of all patients with SCLC as well as those with extensive-stage SCLC over the 1973-to-1994 time period (Fig 2B) .
Our analysis and the results of these other studies show that many of the phase III trials that have been completed over the past 25 years have been small (Ͻ 100 patients per arm) and have insufficient power to detect modest differ-ences (Ͼ 2 months) in survival times between the patients treated with the different regimens being tested. In this analysis, only seven (33%) of the 21 phase III trials enrolled at least 100 patients with extensive-stage SCLC onto each treatment arm and two (29%) of these seven showed a significant difference between the control and experimental arm (Table 1 ). In contrast, 14 (67%) of the 21 studies had fewer than 100 patients on at least one study arm and only three (21%) of the 14 showed a significant difference in the treatment outcomes.
The differences in median survival times between patients with extensive-stage SCLC treated on experimental versus control arms have been small, even in the five studies that had a significant difference in survival times between the two arms. Only one of five trials had a difference of more than 2 months in median survival time between those patients treated with an experimental regimen and those treated with a control regimen. 13 We believe that future trials designed for patients with extensive-stage SCLC should incorporate this information. Differences in median survival times in excess of 2 months are unlikely, so the trials should be sized appropriately. For example, for patients with extensive-stage SCLC, if one assumes a median survival time of 9 months in the control arm, a 2-month improvement is a 22% improvement. To detect a 22% improvement, the total sample size requirement is 840 patients for a power of 0.80. 36 The new regimens brought forth in pilot and phase II studies have rarely led to significant prolongation in survival for patients with extensive-stage SCLC in phase III studies. We are currently developing a statistical model based on the results of the phase III trials for extensive-stage SCLC reported here that may assist investigators in deciding which pilot/phase II regimens are likely to prolong survival when tested in a phase III trial. 37 
